June 2019 - Volume 3 - Issue - Contributor Index

CRITICAL ANALYSIS OF THE STRINGENT COMPLETE RESPONSE IN MULTIPLE MYELOMA. AN UPDATED OF THE ANALYSIS BASED ON THE PETHEMA/GEM2012MENOS65 PHASE III CLINICAL TRIAL: PS1351

Ubieto, Jiménez A.; Martinez-Lopez, J.; Paiva, B.; More

HemaSphere. 3:617, June 2019.

Author:
Ucar, M. A.
Author:
Uccella, S.

MYD88L265P MUTATION IN WM AND IGM-MGUS: COMPARISON OF FEASIBILITY AND BENEFIT BETWEEN DDPCR AND STANDARD ASQPCR IN CD19+ SELECTED AND UNSELECTED SAMPLES: PS1319

Drandi, D.; Furlan, D.; Ferrante, M.; More

HemaSphere. 3:602, June 2019.

Author:
Uchida, N.
Author:
Uchimaru, K.
Author:
Uchino, K.
Author:
Uchino, Y.
Author:
Uchiyama, H.
Author:
Uchiyama, M.
Author:
Uchiyama, T.
Author:
Uda, S.
Author:
Ueda, R.
Author:
Ueda, T.
Author:
Ueda, Y.

NGS-BASED COPY-NUMBER ANALYSIS IN MORE THAN 2,000 PATIENTS WITH MYELOID NEOPLASMS: S135

Saiki, R.; Shiozawa, Y.; Yoshizato, T.; More

HemaSphere. 3:19-20, June 2019.

THE RELATIONSHIP BETWEEN THE PRETREATMENT PNH CLONE SIZE AND CLINICAL COURSE IN PATIENTS WITH BONE MARROW FAILURE SYNDROMES: INTERIM ANALYSIS OF JAPANESE MULTICENTER PROSPECTIVE STUDY: PS1115

Ueda, Y.; Hosokawa, K.; Ishiyama, K.; More

HemaSphere. 3:504-505, June 2019.

Author:
Uemura, S.
Author:
Ueno, H.

REDUCED-INTENSITY IMMUNOCHEMOTHERAPY WITHOUT VINCRISTINE IN ELDERLY PATIENTS OLDER THAN 80 YEARS OLD WITH DIFFUSE LARGE B-CELL LYMPHOMA: A MULTICENTRE, OPEN-LABEL, SINGLE-ARM, PHASE II TRIAL: PF301

Yoshida, I.; Suehiro, Y.; Hirabayashi, Y.; More

HemaSphere. 3:102-103, June 2019.

INTEGRATED PROFILING OF DNA METHYLATION AND MUTATIONS IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES: PF532

Morimoto, S.; Makishima, H.; Nagata, Y.; More

HemaSphere. 3:218-219, June 2019.

COMPREHENSIVE GENETIC ANALYSIS OF MULTIPLE MYELOMA IN JAPAN: PS1367

Kanamori, T.; Sanada, M.; Ri, M.; More

HemaSphere. 3:624-625, June 2019.

Author:
Ufkin, M.

EMERGING CLINICAL ACTIVITY OF REGN1979, AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY (AB), IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) B-CELL NON-HODGKIN LYMPHOMA (B-NHL): S868

Bannerji, R.; Arnason, J.; Advani, R.; More

HemaSphere. 3:388-389, June 2019.

Author:
Ugalde, L.
Author:
Ugo, V.
Author:
Uher, F.
Author:
Uhlar, C.

IMPACT OF AGE ON EFFICACY AND SAFETY OF DARATUMUMAB IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE (D-RD) IN PATIENTS WITH TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): MAIA: PF592

Hulin, C.; Facon, T.; Kumar, S.; More

HemaSphere. 3:248-249, June 2019.

Author:
Uhlig, J.
Author:
Uhlig, K.
Author:
Uike, N.

LONG-TERM FOLLOW-UP OF JCOG0406 STUDY: INTENSIVE IMMUNOCHEMOTHERAPY (R-HIGH CHOP/CHASER) FOLLOWED BY HIGH-DOSE CHEMOTHERAPY (LEED) WITH AUTO-PBSCT IN UNTREATED MANTLE CELL LYMPHOMA: PS1259

Ogura, M.; Yamamoto, K.; Morishima, Y.; More

HemaSphere. 3:575-576, June 2019.

Author:
Ujjani, C.

FACTORS IMPACTING TREATMENT SELECTION IN TREATMENT-NAÏVE PATIENTS WITH CLL: A MULTICENTER STUDY: PF381

Rhodes, J.; Sail, K.; Yazdy, Sarraf M.; More

HemaSphere. 3:142, June 2019.

Author:
Ukai, S.
Author:
Ukimeraj, A.
Author:
Ukropec, J.

EFFICACY AND SAFETY OF DARATUMUMAB, LENALIDOMIDE, AND DEXAMETHASONE (D-RD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED SUBGROUP ANALYSIS OF POLLUX BASED ON CYTOGENETIC RISK: PF591

Dimopoulos, M. A.; San-Miguel, J.; White, D.; More

HemaSphere. 3:247-248, June 2019.

EFFICACY AND SAFETY OF DARATUMUMAB, BORTEZOMIB, AND DEXAMETHASONE (D-VD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED SUBGROUP ANALYSIS OF CASTOR BASED ON CYTOGENETIC RISK: PF596

Weisel, K.; Spencer, A.; Lentzsch, S.; More

HemaSphere. 3:251, June 2019.

UPDATED RISK STRATIFICATION MODEL FOR SMOLDERING MULTIPLE MYELOMA (SMM) INCORPORATING THE REVISED IMWG DIAGNOSTIC CRITERIA: PS1349

Mateos, M.-V.; Kumar, S.; Gonzalez, V.; More

HemaSphere. 3:616, June 2019.

Author:
Ulianchenko, K.

PHARMACO-ECONOMY ANALYSIS OF THE THREATMENT WITH R-DA-EPOCH, R-CHOP, AND CHOP-LIKE REGIMENS IN HIGH-RISK PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (UKRAINIAN MULTICENTER STUDY): PB1812

Filonenko, K.; Kriachok, I.; Martynchyk, A.; More

HemaSphere. 3:830-831, June 2019.

PROGNOSTICATION OF HODGKIN'S LYMPHOMA BY IPET AND IPS: UPDATE DATA OF 8 HEMATOLOGICAL UKRAINIAN CENTERS.: PB1996

Novosad, O.; Skrypets, T.; Pastushenko, I.; More

HemaSphere. 3:903-904, June 2019.

Author:
Ulkuden, B.
Author:
Ulsperger, E.

MYELOMONOCYTIC SKEWING IN CHRONIC MYELOMONOCYTIC LEUKEMIA: PHENOTYPIC, GENOTYPIC AND BIOLOGIC FEATURES AND IMPACT ON SURVIVAL: PS1331

Geissler, K.; Jäger, E.; Barna, A.; More

HemaSphere. 3:607-608, June 2019.

Author:
Ulu, Uncu B.
Author:
Ulusoy, Y.
Author:
Umaña, P.

TARGETING WILMS TUMOR 1 WITH A T CELL BISPECIFIC ANTIBODY (WT1-TCB): EX VIVO AND IN VIVO POTENCY BY BIVALENT RECOGNITION OF PEPTIDE-MHC COMPLEXES FROM AN INTRACELLULAR TUMOR ANTIGEN: PF207

Augsberger, C.; Klein, C.; Heitmüller, C.; More

HemaSphere. 3:56, June 2019.

Author:
Umarova, B.
Author:
Umit, E.
Author:
Umlauff, L.
Author:
Ünal, A.

CLINICAL FEATURES AND TREATMENT OUTCOMES OF CHRONIC PHASE-CHRONIC MYELOID LEUKEMIA PATIENTS IN TURKEY: REAL-WORLD DATA: PB1933

Saydam, G.; Ünal, A.; Kurtoglu, E.; More

HemaSphere. 3:879, June 2019.

Author:
Unal, E.
Author:
Unger, T.

A RANDOMIZED, OPEN-LABEL, PHASE II STUDY OF SELINEXOR VERSUS PHYSICIAN'S CHOICE (PC) IN OLDER PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML): PF261

Sweet, K.; Blum, W.; Donner, H.; More

HemaSphere. 3:82-83, June 2019.

Author:
Ungerstedt, J.

IMPACT OF 1ST LINE TREATMENT ON OVERALL SURVIVAL IN 1.633 PATIENTS WITH CHRONIC MYELOMONOCYTIC LEUKEMIA - A MULTINATIONAL COLLABORATIVE EFFORT COORDINATED BY THE AGMT STUDY GROUP: S840

Pleyer, L.; Leisch, M.; Kouraklis, A.; More

HemaSphere. 3:374-375, June 2019.

Author:
Unuvar, A.
Author:
Uoshima, N.

NGS-BASED COPY-NUMBER ANALYSIS IN MORE THAN 2,000 PATIENTS WITH MYELOID NEOPLASMS: S135

Saiki, R.; Shiozawa, Y.; Yoshizato, T.; More

HemaSphere. 3:19-20, June 2019.

TREATMENT-FREE REMISSION IN PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA FOLLOWING FIRST-LINE DASATINIB, 1ST DADI/IMIDAS4: PF407

Murai, K.; Kimura, S.; Imagawa, J.; More

HemaSphere. 3:155-156, June 2019.

Author:
Upasani, S.

PROGNOSTIC TESTING AND TREATMENT APPROACHES BASED ON REAL-WORLD CLINICAL EXPERIENCE FROM AN INTERIM ANALYSIS OF THE INFORMCLL REGISTRY OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: PF383

Mato, A. R.; Barrientos, J. C.; Brander, D.; More

HemaSphere. 3:143-144, June 2019.

Author:
Ural, A. U.
Author:
Uranga, A.
Author:
Urb, M.
Author:
Urbankova, H.
Author:
Urbano, M.

INFECTIOUS COMPLICATIONS FOLLOWING ARI-0001 CELL (A3B1:CD8:4-1BB:CD3Z CART19) TREATMENT IN ADULT AND PEDIATRIC PATIENTS WITH CD19+ RELAPSED / REFRACTORY MALIGNANCIES: PS1214

Ortiz-Maldonado, V.; Alonso-Saladrigues, A.; Cardozo, C.; More

HemaSphere. 3:553-554, June 2019.

FRACTIONATED DOSING OF ARI-0001 CELLS (A3B1:CD8:4-1BB:CD3Z CAR19) AND EARLY TOCILIZUMAB ADMINISTRATION MAY REDUCE THE INCIDENCE OF SEVERE CYTOKINE RELEASE SYNDROME IN PATIENTS WITH CD19+ MALIGNANCIES: S1636

Ortiz-Maldonado, V.; Alonso-Saladrigues, A.; Caballero-Baños, M.; More

HemaSphere. 3:756, June 2019.

Author:
Urbanova, R.
Author:
Ureshino, H.

TREATMENT-FREE REMISSION IN PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA FOLLOWING FIRST-LINE DASATINIB, 1ST DADI/IMIDAS4: PF407

Murai, K.; Kimura, S.; Imagawa, J.; More

HemaSphere. 3:155-156, June 2019.

Author:
Uriarte, J.
Author:
Uroševic, I.
Author:
Urreta, I.
Author:
Ursu, C. E.
Author:
Ursuleac, I.
Author:
Uryu, H.
Author:
Usala, E.

OPTIMIZATION OF TKI TREATMENT IN ELDERLY PATIENTS WITH PH+ CHRONIC MYELOID LEUKEMIA AND STABLE MR3.0 OR MR4.0: 1ST YEAR RESULTS OF THE ITALIAN MULTICENTRIC PHASE-III RANDOMIZED OPTKIMA STUDY: S882

Malagola, M.; Efficace, F.; Polverelli, N.; More

HemaSphere. 3:396-397, June 2019.

Author:
Ushijima, T.
Author:
Ushiki, T.
Author:
Usikova, E.

PD-1 PATHWAY IS A KEY IMMUNOSUPPRESSIVE MECHANISM IN PATIENTS AFTER HAPLOIDENTICAL STEM CELL TRANSPLANTATION WITH TCR AB-DEPLETION: PF755

Popova, N.; Drokov, M.; Davydova, Y.; More

HemaSphere. 3:331-332, June 2019.

SPLEEN SIZE AS CLINICAL RISK FACTOR FOR GRAFT FAILURE FOLLOWING ALLOGENEIC STEM CELL TRANSPLANTATION IN ACUTE LEUKEMIA PATIENTS: PB2322

Drokov, M.; Maslikova, U.; Kuzmina, L.; More

HemaSphere. 3:1035, June 2019.

CMV-SPECIFIC T-CELL RECONSTITUTION AS A KEY FACTOR FOR IDENTIFICATION OF CANDIDATES FOR CMV-SPECIFIC LYMPHOCYTES INFUSION: PB2328

Dmitrova, A.; Shmarov, V.; Drokov, M.; More

HemaSphere. 3:1037, June 2019.

Author:
Usmani, S.

COMPARATIVE EFFECTIVENESS OF TRIPLETS CONTAINING BORTEZOMIB (B), CARFILZOMIB (C), DARATUMUMAB (D), OR IXAZOMIB (I) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) IN ROUTINE CARE IN THE US: PS1419

Davies, F.; Rifkin, R.; Costello, C.; More

HemaSphere. 3:652-653, June 2019.

Author:
Usmani, S. Z.

EFFICACY AND SAFETY OF DARATUMUMAB, LENALIDOMIDE, AND DEXAMETHASONE (D-RD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED SUBGROUP ANALYSIS OF POLLUX BASED ON CYTOGENETIC RISK: PF591

Dimopoulos, M. A.; San-Miguel, J.; White, D.; More

HemaSphere. 3:247-248, June 2019.

IMPACT OF AGE ON EFFICACY AND SAFETY OF DARATUMUMAB IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE (D-RD) IN PATIENTS WITH TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): MAIA: PF592

Hulin, C.; Facon, T.; Kumar, S.; More

HemaSphere. 3:248-249, June 2019.

Show: